These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16751605)

  • 21. Specific inhibition of binding of antistasin and [A103,106,108] antistasin 93-119 to sulfatide (Gal(3-SO4)beta 1-1Cer) by glycosaminoglycans.
    Brankamp RG; Manley GD; Owen TJ; Krstenansky JL; Cardin AD
    FEBS Lett; 1992 Jan; 296(2):145-7. PubMed ID: 1733769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of heparin on the physicochemical properties of reconstituted collagen.
    McPherson JM; Sawamura SJ; Condell RA; Rhee W; Wallace DG
    Coll Relat Res; 1988 Jan; 8(1):65-82. PubMed ID: 3126021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts.
    Martin EB; Williams A; Heidel E; Macy S; Kennel SJ; Wall JS
    Biochem Biophys Res Commun; 2013 Jun; 436(1):85-9. PubMed ID: 23707811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferation of cultured fibroblasts is inhibited by L-iduronate-containing glycosaminoglycans.
    Westergren-Thorsson G; Onnervik PO; Fransson LA; Malmström A
    J Cell Physiol; 1991 Jun; 147(3):523-30. PubMed ID: 2066370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macromolecular properties of glycosaminoglycans in primary AL amyloid fibril extracts of lymphoid tissue origin.
    Stenstad T; Magnus JH; Kolset SO; Cornwell GG; Husby G
    Scand J Immunol; 1991 Nov; 34(5):611-7. PubMed ID: 1947796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of acetaldehyde-glycosaminoglycan mixtures upon Factor IXa and Factor IX-Deficient Plasma.
    Brecher AS; Moon AR; Gray KD
    Alcohol; 2006 Jun; 39(2):97-104. PubMed ID: 17134662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity.
    Iannuzzi C; Irace G; Sirangelo I
    Molecules; 2015 Feb; 20(2):2510-28. PubMed ID: 25648594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sepharose-bound, highly sulfated glycosaminoglycans can capture HIV-1 from culture medium.
    Curatella B; Bartolini B; Di Caro A; Cavallaro RA; Liverani L; Mascellani G; Benedetto A; Castilletti C; Capobianchi MR; Cellai L
    Carbohydr Res; 2005 Mar; 340(4):759-64. PubMed ID: 15721350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycosaminoglycan specificity of a heparin-binding peptide.
    Taylor GJ; Yorke SC; Harding DR
    Pept Res; 1995; 8(5):286-93. PubMed ID: 8589551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current concepts on the pathogenesis of systemic amyloidosis.
    Bellotti V; Merlini G
    Nephrol Dial Transplant; 1996; 11 Suppl 9():53-62. PubMed ID: 9050036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
    Picken MM
    Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction.
    Martin DJ; Ramirez-Alvarado M
    Biophys Chem; 2011 Sep; 158(1):81-9. PubMed ID: 21640469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of Light Chain 6aJL2-R24G Amyloid Fiber Formation Associated with Light Chain Amyloidosis.
    Pelaez-Aguilar AE; Rivillas-Acevedo L; French-Pacheco L; Valdes-Garcia G; Maya-Martinez R; Pastor N; Amero C
    Biochemistry; 2015 Aug; 54(32):4978-86. PubMed ID: 26214579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen.
    Ohishi H; Skinner M; Sato-Araki N; Okuyama T; Gejyo F; Kimura A; Cohen AS; Schmid K
    Clin Chem; 1990 Jan; 36(1):88-91. PubMed ID: 2297939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of glycosaminoglycans on the growth of cultured tumor cells.
    Nagasawa S
    J Osaka Dent Univ; 1993 Oct; 27(2):121-33. PubMed ID: 8182504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathogenesis, diagnosis and treatment of systemic amyloidosis.
    Pepys MB
    Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
    Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
    Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
    Bellotti V; Mangione P; Merlini G
    J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic immunoglobulin light-chain amyloidosis.
    Comenzo RL
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
    Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
    J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.